eISSN: 1644-4124
ISSN: 1426-3912
Central European Journal of Immunology
Current issue Archive Manuscripts accepted About the journal Abstracting and indexing Subscription Contact Instructions for authors
SCImago Journal & Country Rank

2/2018
vol. 43
 
Share:
Share:
more
 
 
abstract:
Clinical immunology

IL-35 inhibits human osteoclastogenesis from monocytes induced by receptor-activator of NF-κB ligand

Toru Yago, Yuki Nanke, Manabu Kawamoto, Tsuyoshi Kobashigawa, Hisashi Yamanaka, Shigeru Kotake

(Centr Eur J Immunol 2018; 43 (2): 148-154)
Online publish date: 2018/06/30
View full text
Get citation
ENW
EndNote
BIB
JabRef, Mendeley
RIS
Papers, Reference Manager, RefWorks, Zotero
AMA
APA
Chicago
Harvard
MLA
Vancouver
 
IL-35 is known as a regulatory cytokine produced by regulatory T cells. It has also been reported that IL-35 suppresses the proliferation of Th17 cells, which is involved in the pathogenesis of many autoimmune diseases. However, in rheumatoid arthritis patients, the role of IL-35 is controversial, and the role of IL-35 in bone metabolism has not been clarified. We investigated the effect of IL-35 on human osteoclast differentiation and activation. We first evaluated the effect of rhIL-35 on human osteoclastogenesis from monocytes cultured alone, induced by soluble-RANKL. We also examined the role of IL-35 on the bone-resorption function of mature osteoclasts. Furthermore, we analysed the molecular mechanism of IL-35 function in monocytes or pre-osteoclasts using RT-PCR. rhIL-35 significantly inhibited human osteoclastogenesis in a dose-dependent manner. In addition, rhIL-35 also significantly decreased the area of pit formation by mature osteoclasts. rhIL-35 significantly decreased mRNA expression of RANK in monocytes and RANK and FOS in pre-osteoclasts. Our current findings suggest that IL-35 inhibits osteoclastogenesis and osteoclast activation by inhibiting both RANK and FOS. IL-35 also has an inhibitory effect on osteoclastic-bone resorption, suggesting that IL-35 may have a therapeutic potential for RA.
keywords:

osteoclasts, monocytes, RANKL, Interleukin-35, osteoclastogenesis

references:
Collison LW, Delgoffe GM, Guy CS, et al. (2012): The composition and signaling of the IL-35 receptor are unconventional. Nat Immunol 13: 290-299.
Trinchieri G. (2003): Interleukin-12 and the regulation of innate resistance and adaptive immunity. Nat Rev Immunol 3: 133-146.
Bardel E, Larousserie F, Charlot-Rabiega P, et al. (2008): Human CD4+ CD25+ Foxp3+ regulatory T cells do not constitutively express IL-35. J Immunol 181: 6898-6905.
Collison LW, Vignali DA. (2008): Interleukin-35: odd one out or part of the family? Immunol Rev 226: 248-262.
Vignali DA, Collison LW, Workman CJ. (2008): How regulatory T cells work. Nat Rev Immunol 8: 523-532.
Banchereau J, Pascual V, O’Garra A. (2012): From IL-2 to IL-37: the expanding spectrum of anti-inflammatory cytokines. Nat Immunol 13: 925-931.
Collison LW, Workman CJ, Kuo TT, et al. (2007): The inhibitory cytokine IL-35 contributes to regulatory T-cell function. Nature 450: 566-569.
Bettini M, Vignali DA. (2009): Regulatory T cells and inhibitory cytokines in autoimmunity. Curr Opin Immunol 21: 612-618.
Astry B, Harberts E, Moudgil KD. (2011): A cytokine-centric view of the pathogenesis and treatment of autoimmune arthritis. J Interferon Cytokine Res 31: 927-940.
Pillai MR, Collison LW, Wang X, et al. (2011): The plasticity of regulatory T cell function. J Immunol 187: 4987-4997.
Clavel G, Thiolat A, Boissier MC. (2013): Interleukin newcomers creating new numbers in rheumatology: IL-34 to IL-38. Joint Bone Spine 80: 449-453.
Jafarzadeh A, Jamali M, Mahdavi R, et al. (2015): Circulating levels of interleukin-35 in patients with multiple sclerosis: evaluation of the influences of FOXP3 gene polymorphism and treatment program. J Mol Neurosci 55: 891-897.
Bettini M, Castellaw AH, Lennon GP, et al. (2012): Prevention of autoimmune diabetes by ectopic pancreatic -cell expression of interleukin-35. Diabetes. 61: 1519-1526.
Thiolat A, Denys A, Petit M, et al. (2014): Interleukin-35 gene therapy exacerbates experimental rheumatoid arthritis in mice. Cytokine 69: 87-93.
Kuo J, Nardelli DT, Warner TF, et al. (2011): Interleukin-35 enhances Lyme arthritis in Borrelia-vaccinated and -infected mice. Clin Vaccine Immunol 18: 1125-1132.
Niedbala W, Wei XQ, Cai B, et al. (2007): IL-35 is a novel cytokine with therapeutic effects against collagen-induced arthritis through the expansion of regulatory T cells and suppression of Th17 cells. Eur J Immunol 37: 3021-3029.
Filková M, Vernerová Z, Hulejová H, et al. (2015): Pro-inflammatory effects of interleukin-35 in rheumatoid arthritis. Cytokine 73: 36-43.
Šenolt L, Šumová B, Jandová R, et al. (2015): Interleukin 35 Synovial Fluid Levels Are Associated with Disease Activity of Rheumatoid Arthritis. PLoS One 10: e0132674.
Nakano S, Morimoto S, Suzuki S, et al. (2015): Immunoregulatory role of IL-35 in T cells of patients with rheumatoid arthritis. Rheumatology (Oxford) 54: 1498-1506.
Li Y, Li D, Li Y, et al. (2016): Interleukin-35 upregulates OPG and inhibits RANKL in mice with collagen-induced arthritis and fibroblast-like synoviocytes. Osteoporos Int. [Epub ahead of print]
Kotake S, Nanke Y, Mogi M, et al. (2005): IFN-gamma-producing human T cells directly induce osteoclastogenesis from human monocytes via the expression of RANKL. Eur J Immunol 35: 3353-3363.
Yago T, Nanke Y, Kawamoto M, et al. (2007): IL-23 induces human osteoclastogenesis via IL-17 in vitro, and anti-IL-23 antibody attenuates collagen-induced arthritis in rats. Arthritis Res Ther 9: R96.
Yago T, Nanke Y, Ichikawa N, et al. (2009): IL-17 induces osteoclastogenesis from human monocytes alone in the absence of osteoblasts, which is potently inhibited by anti-TNF-αlpha antibody: a novel mechanism of osteoclastogenesis by IL-17. J Cell Biochem 108: 947-955.
Kotake S, Udagawa N, Takahashi N, et al. (1999): IL-17 in synovial fluids from patients with rheumatoid arthritis is a potent stimulator of osteoclastogenesis. J Clin Invest 103:1345-1352.
Kalliolias GD, Zhao B, Triantafyllopoulou A, et al. (2010): Interleukin-27 inhibits human osteoclastogenesis by abrogating RANKL-mediated induction of nuclear factor of activated T cells c1 and suppressing proximal RANK signaling. Arthritis Rheum 62: 402-413.
Nagata N, Kitaura H, Yoshida N, et al. (2003): Inhibition of RANKL-induced osteoclast formation in mouse bone marrow cells by IL-12: involvement of IFN-gamma possibly induced from non-T cell population. Bone 33: 721-732.
Furukawa M, Takaishi H, Takito J, et al. (2009): IL-27 abrogates receptor activator of NF-kappa B ligand-mediated osteoclastogenesis of human granulocyte-macrophage colony-forming unit cells through STAT1-dependent inhibition of c-Fos. J Immunol 183: 2397-2406.
Palmqvist P, Persson E, Conaway HH, et al. (2002): IL-6, leukemia inhibitory factor, and oncostatin M stimulate bone resorption and regulate the expression of receptor activator of NF-kappa B ligand, osteoprotegerin, and receptor activator of NF-kappa B in mouse calvariae. J Immunol 169: 3353-3362.
Duplomb L, Baud’huin M, Charrier C, et al. (2008): Interleukin-6 inhibits receptor activator of nuclear factor kappaB ligand-induced osteoclastogenesis by diverting cells into the macrophage lineage: key role of Serine727 phosphorylation of signal transducer and activator of transcription 3. Endocrinology 149: 3688-3697.
Kotake S, Nanke Y, Yago T, et al. (2009): Human osteoclastogenic T cells and human osteoclastology. Arthritis Rheum 60: 3158-3163.
Kochetkova I, Golden S, Holderness K, et al. (2010): IL-35 stimulation of CD39+ regulatory T cells confers protection against collagen II-induced arthritis via the production of IL-10. J Immunol 184: 7144-7153.
FEATURED PRODUCTS
Quick links
© 2018 Termedia Sp. z o.o. All rights reserved.
Developed by Bentus.
PayU - płatności internetowe